• Mutation; VGNC; VGNC:38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468).
  

PubMed=15585963; DOI=10.1292/jvms.66.1437
Inoue K., Ohashi E., Kadosawa T., Hong S.-H., Matsunaga S., Mochizuki M., Nishimura R., Sasaki N.
Establishment and characterization of four canine melanoma cell lines.
J. Vet. Med. Sci. 66:1437-1440(2004)

PubMed=24035468; DOI=10.1016/j.tvjl.2013.08.003
Ito K., Kobayashi M., Kuroki S., Sasaki Y., Iwata T., Mori K., Kuroki T., Ozawa Y., Tetsuka M., Nakagawa T., Hiroi T., Yamamoto H., Ono K., Washizu T., Bonkobara M.
The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
Vet. J. 198:577-582(2013)

PubMed=28283079; DOI=10.1016/j.tvjl.2017.02.001
Yoshitake R., Saeki K., Watanabe M., Nakaoka N., Ong S.M., Hanafusa M., Choisunirachon N., Fujita N., Nishimura R., Nakagawa T.
Molecular investigation of the direct anti-tumour effects of nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell lines.
Vet. J. 221:38-47(2017)

PubMed=30268330; DOI=10.1016/j.tvjl.2018.09.001
Miyamoto R., Kurita S., Tani H., Ikeda T., Ishizaka M., Saima H., Kobayashi M., Tamura K., Bonkobara M.
Canine squamous cell carcinoma cell lines with high expression of survivin are sensitive to survivin inhibitor YM155.
Vet. J. 240:31-36(2018)